kourosh Lotfi
kourosh Lotfi
Associate professor, Linkoeping university
Verified email at liu.se
Title
Cited by
Cited by
Year
Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial
S Saussele, J Richter, J Guilhot, FX Gruber, H Hjorth-Hansen, A Almeida, ...
The Lancet Oncology 19 (6), 747-757, 2018
2602018
Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia
M Ilander, U Olsson-Strömberg, H Schlums, J Guilhot, O Brück, ...
Leukemia 31 (5), 1108-1116, 2017
1502017
Musculoskeletal pain in patients with chronic myeloid leukemia after discontinuation of imatinib: a tyrosine kinase inhibitor withdrawal syndrome?
J Richter, S Söderlund, A Lübking, A Dreimane, K Lotfi, B Markevärn, ...
Journal of Clinical Oncology 32 (25), 2821-2823, 2014
1132014
Biochemical pharmacology and resistance to 2-chloro-2′-arabino-fluoro-2′-deoxyadenosine, a novel analogue of cladribine in human leukemic cells
K Lotfi, E Månsson, T Spasokoukotskaja, B Pettersson, J Liliemark, ...
Clinical cancer research 5 (9), 2438-2444, 1999
1071999
Comparison of idarubicin and daunorubicin regarding intracellular uptake, induction of apoptosis, and resistance
K Lotfi, AL Zackrisson, C Peterson
Cancer letters 178 (2), 141-149, 2002
672002
Lymphocytes eject interferogenic mitochondrial DNA webs in response to CpG and non-CpG oligodeoxynucleotides of class C
B Ingelsson, D Söderberg, T Strid, A Söderberg, AC Bergh, V Loitto, ...
Proceedings of the National Academy of Sciences 115 (3), E478-E487, 2018
602018
Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase‐2 study (N ord CML 006)
H Hjorth‐Hansen, L Stenke, S Söderlund, A Dreimane, H Ehrencrona, ...
European journal of haematology 94 (3), 243-250, 2015
572015
Association of ABCB1 polymorphisms with survival and in vitro cytotoxicty in de novo acute myeloid leukemia with normal karyotype
H Green, IJ Falk, K Lotfi, E Paul, M Hermansson, R Rosenquist, C Paul, ...
The pharmacogenomics journal 12 (2), 111-118, 2012
562012
Pharmacological basis for cladribine resistance in a human acute T lymphoblastic leukaemia cell line selected for resistance to etoposide
K Lotfi, E Månsson, J Chandra, Y Wang, D Xu, E Knaust, ...
British journal of haematology 113 (2), 339-346, 2001
472001
CYP3A activity influences imatinib response in patients with chronic myeloid leukemia: a pilot study on in vivo CYP3A activity
H Gréen, K Skoglund, F Rommel, RA Mirghani, K Lotfi
European journal of clinical pharmacology 66 (4), 383-386, 2010
392010
Association between TERT promoter polymorphisms and acute myeloid leukemia risk and prognosis
MA Mosrati, K Willander, IJ Falk, M Hermanson, M Höglund, ...
Oncotarget 6 (28), 25109, 2015
382015
A prospective evaluation of patients' health-related quality of life during auto-SCT: a 3-year follow-up
U Frödin, S Börjeson, J Lyth, K Lotfi
Bone marrow transplantation 46 (10), 1345-1352, 2011
372011
Pharmacological basis for cladribine resistance
K Lotfi, G Juliusson, F Albertioni
Leukemia & lymphoma 44 (10), 1705-1712, 2003
342003
Low level of mitochondrial deoxyguanosine kinase is the dominant factor in acquired resistance to 9-β-D-arabinofuranosylguanine cytotoxicity
K Lotfi, E Månsson, C Peterson, S Eriksson, F Albertioni
Biochemical and biophysical research communications 293 (5), 1489-1496, 2002
312002
Mutations in the isocitrate dehydrogenase 2 gene and IDH1 SNP 105C> T have a prognostic value in acute myeloid leukemia
K Willander, IJ Falk, R Chaireti, E Paul, M Hermansson, H Gréen, K Lotfi, ...
Biomarker research 2 (1), 1-9, 2014
292014
Decreased survival in normal karyotype AML with single‐nucleotide polymorphisms in genes encoding the AraC metabolizing enzymes cytidine deaminase and 5′‐nucleotidase
IJ Falk, A Fyrberg, E Paul, H Nahi, M Hermanson, R Rosenquist, ...
American journal of hematology 88 (12), 1001-1006, 2013
292013
The pattern of deoxycytidine-and deoxyguanosine kinase activity in relation to messenger RNA expression in blood cells from untreated patients with B-cell chronic lymphocytic …
K Lotfi, K Karlsson, A Fyrberg, G Juliusson, V Jonsson, C Peterson, ...
Biochemical pharmacology 71 (6), 882-890, 2006
292006
Glucose starvation-mediated inhibition of salinomycin induced autophagy amplifies cancer cell specific cell death
JR Jangamreddy, MV Jain, AL Hallbeck, K Roberg, K Lotfi, MJ Łos
Oncotarget 6 (12), 10134, 2015
252015
Mapping of apoptin-interaction with BCR-ABL1, and development of apoptin-based targeted therapy
JR Jangamreddy, S Panigrahi, K Lotfi, M Yadav, S Maddika, AK Tripathi, ...
Oncotarget 5 (16), 7198, 2014
192014
Duration of Deep Molecular Response Has Most Impact on the Success of Cessation of Tyrosine Kinase Inhibitor Treatment in Chronic Myeloid Leukemia-Results from the EURO-SKI Trial
S Saussele, J Richter, J Guilhot, H Hjorth-Hansen, AM Almeida, ...
Blood 130 (Supplement 1), 313-313, 2017
182017
The system can't perform the operation now. Try again later.
Articles 1–20